<DOC>
	<DOCNO>NCT01473147</DOCNO>
	<brief_summary>Background : Continuous subcutaneous insulin infusion ( CSII ) demonstrate effective clinical tool intensive insulin therapy Type 1 diabetic patient . Type 2 diabetes patient prove decreased glucagon-like peptide-1 ( GLP-1 ) level . Injection GLP-1 receptor agonist associate improved glycemic control . Nevertheless , clinical effect mechanisms still unclear additional supplement GLP-1 analogue cooperation intensive CSII treatment poorly control Type 2 diabetes patient . This study design understand complementary pharmacological effect GLP-1 analogue intensive CSII treatment . Methods : Sixty poorly control Type 2 diabetes patient admit ward 6 day CSII intensive treatment . Following normalization blood glucose first 3 day , patient randomly assign combined therapy exenatide injection saline another 3 day . The clinical assessment insulin requirement , insulin secretion , insulin resistance glycemic excursion cytokine perform immediately study .</brief_summary>
	<brief_title>Additional GLP-1 Analogue CSII Treatment Poorly Controlled Type 2 Diabetic Patients</brief_title>
	<detailed_description>In poorly control type 2 DM , insulin therapy treatment choice make sugar target . Actually , however , general control rate good partially due complex etiology type 2 DM . GLP-1 deficiency mostly emphasize modern practice . In order study effect GLP-1 analogue insulinized type 2 DM patient , investigator optimize insulin therapy first priority . Continuous subcutaneous insulin infusion ( CSII ) insulin pump viable choice patient type 1 type 2 DM want close-to-physiologic insulin treatment . By mean insulin pump therapy , standardized sugar control profile type 2 DM patient could achieve short time . Investigators evaluate clinical response GLP-1 analogue .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Age &gt; 20 year old DM diagnose &gt; 2 year HbA1c level 8 % 12 % Receiving insulin premixed insulin twice daily total insulin daily dose &gt; 0.6 u/kg/day Severe comorbidity , include CHF , CVA , liver cirrhosis , COPD , Cushing 's syndrome etc . Psychologic problem , include anxiety Incorporation , include personal familial factor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>GLP-1 analogue</keyword>
	<keyword>CSII</keyword>
	<keyword>insulin</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>